Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMP-101 in DOK7 Congenital Myasthenic Syndrome
NCT07830563Phase 1Not yet recruiting
- Sponsor
- Amplo Biotechnology
- Start
- Oct 2026
- Primary completion
- Oct 2028
01
Overview
Phase 1, open-label, single-arm trial of AMP-101 in congenital myasthenic syndrome (CMS), sponsored by Amplo Biotechnology. Primary endpoints: Treatment-Emergent Adverse Events at Day 180, Adverse Events of Special Interest at Day 180 and 5 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
AMP-101
03
Conditions
congenital myasthenic syndrome (CMS)
Beyond the preview
Go deeper on NCT07830563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07830563.